Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
| Autor: | Requena, S., Lozano, AB., Caballero, E., García, F., Nieto, MC., Téllez, R., Fernández, JM., Trigo, M., Rodríguez-Avial, I., Martín-Carbonero, L., Miralles, P., Soriano, V., de, Mendoza, C., HIV-2 Spanish Study Group, Rodríguez, C., Vera, M., Del, Romero, J., Marcaida, G., Ocete, MD., Aguilera, A., BENITO, R., de, Lejarazu, RO., Rojo, S., Eirós, JM., Ramos, C., García, J., Paz, I., Diz, J., García-Campello, M., Rodríguez-Iglesias, M., Hernández-Betancor, A., Martín, AM., Ramos, JM., Gimeno, A., Sánchez, V., Gómez-Hernando, C., Cilla, G., Pérez-Trallero, E., Fernández-Pereira, L., Niubó, J., Hernández, M., López-Lirola, AM., Gómez-Sirvent, JL., Force, L., Cabrera, J., Pérez, S., Morano, L., Raya, C., González-Praetorius, A., Cifuentes, C., Peñaranda, M., Montejo, JM., Roc, L., Viciana, I., Fernández-Fuertes, E., García-Bermejo, I., Gaspar, G., Górgolas, M., Pérez, L., Valeiro, M., Aldamiz, T., Margall, N., Suárez, A., Benítez-Gutiérrez, L., Cuervas-Mons, V., Barreiro, P. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Zaguán. Repositorio Digital de la Universidad de Zaragoza instname |
| Popis: | Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|